Altre lingue Sensei Biotherapeutics, Inc.

Azioni

SNSE

US81728A1088

Tempo differito Nasdaq Altri mercati azionari 21:58:08 27/06/2024			Variaz. 5gg	Var. 1 gen.
0,6649 ^USD	-0,60%		+11,53%	-2,17%

14/05	SENSEI BIOTHERAPEUTICS, INC. : Stephens Inc. ribadisce il giudizio positivo sul titolo	ZM
09/05	Sensei Biotherapeutics, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Sensei Biotherapeutics : Bio SNS-101 Data Webcast	04/06
Sensei Biotherapeutics : Company Presentation June 2024	01/06
ASCO 2024: Topline SNS-101 Dose Escalation Data	01/06
Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference	30/05
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101	23/05
Sensei Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights	09/05
Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting	24/04
Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting	24/04
Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference	09/04
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment	04/04
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of Vista Within the Tumor Microenvironment	04/04
Sensei Biotherapeutics : Company Presentation April 2024	02/04
Sensei Biotherapeutics, Inc. Announces Resignation of Erin Colgan as Chief Financial Officer, Effective April 10, 2024	02/04
North American Morning Briefing : Stocks Set for -2-	28/03
Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium	22/03
Keystone Symposia 2024: Preclinical data for SNS-101	21/03
Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences	06/03
Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights	28/02
Sensei Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

In prima pagina

SENSEI BIOTHERAPEUTICS : Terzo trimestre contrastato, ma la liquidità rimane intatta

10 novembre 2022 alle 12:59